Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Increased to Buy at UBS Group

Jazz Pharmaceuticals (NASDAQ:JAZZ) was upgraded by research analysts at UBS Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage currently has a $179.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $145.00. UBS Group’s price target would suggest a potential upside of 31.18% from the company’s current price.

Several other research analysts have also issued reports on JAZZ. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $188.87.

Jazz Pharmaceuticals Trading Down 2.7 %

Shares of JAZZ opened at $136.45 on Friday. The company’s fifty day simple moving average is $127.85 and its 200-day simple moving average is $119.83. The company has a market cap of $8.29 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,113 shares of company stock worth $2,551,834 in the last 90 days. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of JAZZ. Fuller & Thaler Asset Management Inc. boosted its stake in Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $59,668,000. Dimensional Fund Advisors LP lifted its stake in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after buying an additional 320,724 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after buying an additional 315,608 shares during the last quarter. Finally, GMT Capital Corp increased its position in shares of Jazz Pharmaceuticals by 140.0% in the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after acquiring an additional 296,800 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.